Is Prenetics Global Ltd. overvalued or undervalued?

As of 5 October 2023, Prenetics Global Ltd. has moved from fair to overvalued. The company's current price-to-earnings ratio stands at 45.2, significantly higher than the industry average of 25.7, indicating that investors are paying a premium for its earnings. Additionally, the price-to-sales ratio is at 8.3, while the industry average is 4.5, further suggesting overvaluation. The return on equity is reported at 5.1%, which is lower than the peer average of 10.2%, highlighting potential inefficiencies in generating profit from equity. In comparison to peers such as LabCorp with a price-to-earnings ratio of 18.5 and Quest Diagnostics at 20.3, Prenetics appears to be priced excessively high relative to its earnings potential. This overvaluation is compounded by the company's recent stock performance, which has lagged behind the Sensex, reinforcing the notion that the current market price may not be justified given its financial metrics.